IE
ELVN icon

Israel Englander’s Enliven Therapeutics ELVN Stock Holding History

Israel Englander’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9M Buy
411,362
+66,044
+19% +$2.8M 0.01% 1585
2026
Q1 		$13.5M Buy
345,318
+48,371
+16% +$1.34M 0.01% 1883
2025
Q4 		$4.57M Sell
296,947
-84,458
-22% -$1.68M ﹤0.01% 3110
2025
Q3 		$7.81M Buy
381,405
+62,956
+20% +$1.27M ﹤0.01% 2642
2025
Q2 		$6.39M Buy
318,449
+185,562
+140% +$3.51M ﹤0.01% 2733
2025
Q1 		$2.62M Buy
132,887
+82,083
+162% +$1.77M ﹤0.01% 3518
2024
Q4 		$1.14M Buy
50,804
+26,449
+109% +$686K ﹤0.01% 4089
2024
Q3 		$622K Buy
+24,355
New +$564K ﹤0.01% 4660
2023
Q2 		– Sell
-46,874
Closed -$1.03M – 6228
2023
Q1 		$1.03M Buy
+46,874
New +$953K ﹤0.01% 4073
2022
Q2 		– Sell
-2,577
Closed -$19K – 7088
2022
Q1 		$19K Sell
2,577
-15,386
-86% -$101K ﹤0.01% 6646
2021
Q4 		$162K Sell
17,963
-7,988
-31% -$105K ﹤0.01% 6038
2021
Q3 		$424K Buy
25,951
+17,235
+198% +$358K ﹤0.01% 5498
2021
Q2 		$275K Buy
8,716
+4,321
+98% +$134K ﹤0.01% 5798
2021
Q1 		$148K Buy
4,395
+4
+0.1% +$203 ﹤0.01% 5593
2020
Q4 		$387K Buy
+4,391
New +$369K ﹤0.01% 4395
2020
Q3 		– Sell
-2,768
Closed -$306K – 4538
2020
Q2 		$306K Buy
+2,768
New +$310K ﹤0.01% 3652

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Israel Englander's ELVN Position: Q2 2026 in Review

Israel Englander increased its Enliven Therapeutics (ELVN) stake by 19% in Q2 2026, buying an estimated $2.8M and bringing the position to 411,362 shares worth $20.9M. The position accounts for 0.01% of the portfolio, ranked #1585.

Israel Englander first reported a position in ELVN in Q2 2020 and has held it in 16 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Israel Englander held 411,362 shares of Enliven Therapeutics worth $20.9M as of Q2 2026.
  • Israel Englander bought 66,044 Enliven Therapeutics shares in Q2 2026, an estimated $2.8M.
  • Enliven Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1585 holding.
  • Israel Englander first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.